Evidence map›Paper›PMID 22561027›Full record

ArticleRadiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology2012

Kinomic profiling approach identifies Trk as a novel radiation modulator.

John S Jarboe, Jerry J Jaboin, Joshua C Anderson, Somaira Nowsheen, Jennifer A Stanley, Faris Naji, Rob Ruijtenbeek, Tianxiang Tu, Dennis E Hallahan, Eddy S Yang and 2 more

Abstract read
In one paragraph

Article in Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.

0numbers the graph read from it
0cells of the map it votes in
17citing papers in PubMed
0.9field-weighted citation impact, top 24% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

17 citing papers in PubMed, 26 citations in OpenAlex.

  1. Trial
  2. Article
  3. Article
  4. Article
  5. Review
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Kinomic exploration of temozolomide and radiation resistance in Glioblastoma multiforme xenolines.Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology · 2014
    Article
  16. Article
  17. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 4 institutions in 2 countries.

John S JarboeDepartment of Biochemistry and Molecular Genetics, The University of Alabama at Birmingham, Birmingham, AL 35249-6832, USA.
Jerry J Jaboin
Joshua C Anderson
Somaira Nowsheen
Jennifer A Stanley
Faris Naji
Rob Ruijtenbeek
Tianxiang Tu
Dennis E Hallahan
Eddy S Yang
James A Bonner
Christopher D Willey
University of Alabama at Birmingham · USPamGene (Netherlands) · NLWashington University in St. Louis · USVanderbilt University · US

Funding

TARGETING NOTCH 3 IN LUNG CANCERP50CA090949 · NCI · VANDERBILT UNIVERSITY · PI MASSION, PIERRE P. · 2001 to 2011
$24.1M
Vanderbilt In Vivo Cellular and Molecular Imaging CenterP50CA128323 · NCI · VANDERBILT UNIVERSITY · PI SHYR, YU · 2008 to 2012
$6.8M
FLK1 SINALING PROTECTS TUMOR VASCULATURE FROM RADIATIONR01CA089674 · NCI · VANDERBILT UNIVERSITY · PI HALLAHAN, DENNIS E · 2001 to 2008
$2.3M
X-ray Targeted Therapeutic Genes within NanoparticlesR01CA125757 · NCI · WASHINGTON UNIVERSITY · PI HALLAHAN, DENNIS E · 2007 to 2011
$1.7M
Lysophospholipids in Radiation Induced Signal Transduction in Malignant GliomasR01CA140220 · NCI · WASHINGTON UNIVERSITY · PI HALLAHAN, DENNIS E · 2010 to 2014
$1.7M
Pharmacodynamic Assessment of RTK Inhibitors in CancerR01CA112385 · NCI · WASHINGTON UNIVERSITY · PI HALLAHAN, DENNIS E · 2005 to 2009
$1.3M
Nanoparticles Targeting Pancreatic CancerR21CA128456 · NCI · WASHINGTON UNIVERSITY · PI HALLAHAN, DENNIS E · 2007 to 2009
$422k
NCI NIH HHS 2R01-CA89674NCI NIH HHS L40 CA136346NCI NIH HHS P50 CA090949NCI NIH HHS P50 CA128323NCI NIH HHS P50-CA90949NCI NIH HHS R01 CA089674NCI NIH HHS R01 CA112385NCI NIH HHS R01-CA112385NCI NIH HHS R01-CA1256757NCI NIH HHS R01 CA125757NCI NIH HHS R01 CA140220NCI NIH HHS R21 CA128456NCI NIH HHS R21-CA128456
6 · The paper itself

Abstract

backgroundIonizing radiation treatment is used in over half of all cancer patients, thus determining the mechanisms of response or resistance is critical for the development of novel treatment approaches. MATERIALS AND

methodsIn this report, we utilize a high-content peptide array platform that performs multiplex kinase assays with real-time kinetic readout to investigate the mechanism of radiation response in vascular endothelial cells. We applied this technology to irradiated human umbilical vein endothelial cells (HUVEC).

resultsWe identified 49 specific tyrosine phosphopeptides that were differentially affected by irradiation over a time course of 1h. In one example, the Tropomyosin receptor kinase (Trk) family members, TrkA and TrkB, showed transient activation between 2 and 15 min following irradiation. When we targeted TrkA and TrkB using small molecule inhibitors, HUVEC were protected from radiation damage. Conversely, stimulation of TrkA using gambogic amide promoted radiation enhancement.

conclusionsThus, we show that our approach not only can identify rapid changes in kinase activity but also identify novel targets such as TrkA. TrkA inhibition resulted in radioprotection that correlated with enhanced repair of radiation-induced damage while TrkA stimulation by gambogic amide produced radiation sensitization.

Indexed as

Radiation ToleranceCell CycleCell LineCells, CulturedCell SurvivalDNA RepairHumansHuman Umbilical Vein Endothelial CellsPhosphorylationProtein Array AnalysisProtein KinasesRadiation DosageReceptor, trkAReceptor, trkBXanthonesgambogic amideProtein KinasesReceptor, trkAReceptor, trkBtropomyosin kinaseXanthones

Identifiers

PMID22561027
PMCPMC3368103
OpenAlexW2074156138

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.